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ABSTRACT
Rpn13 is an intrinsic ubiquitin receptor of the 26S proteasome
regulatory subunit that facilitates substrate capture prior to
degradation. Here we show that the C-terminal region of Rpn13
binds to the tetratricopeptide repeat (TPR) domain of SGTA, a
cytosolic factor implicated in the quality control of mislocalised
membrane proteins (MLPs). The overexpression of SGTA results in
a substantial increase in steady-state MLP levels, consistent with an
effect on proteasomal degradation. However, this effect is strongly
dependent upon the interaction of SGTA with the proteasomal
component Rpn13. Hence, overexpression of the SGTA-binding
region of Rpn13 or point mutations within the SGTATPR domain both
inhibit SGTA binding to the proteasome and substantially reduceMLP
levels. These findings suggest that SGTA can regulate the access of
MLPs to the proteolytic core of the proteasome, implying that a protein
quality control cycle that involves SGTA and the BAG6 complex can
operate at the 19S regulatory particle. We speculate that the binding
of SGTA to Rpn13 enables specific polypeptides to escape
proteasomal degradation and/or selectively modulates substrate
degradation.
KEY WORDS: Bag6, Mislocalised proteins, Proteasomes, Protein
degradation, TPR, Ubiquitylation
INTRODUCTION
The ubiquitin-proteasome system (UPS) constitutes a main pathway
for protein degradation in eukaryotic cells, with polypeptides
destined for disposal via this route bearing ubiquitin chains. The
selective and covalent attachment of the small ubiquitin polypeptide
to these proteins is typically through lysine residues within the
substrates and occurs through a cascade of sequential reactions
catalysed by E1, E2 and E3 enzymes (Komander and Rape, 2012).
Furthermore, ubiquitin itself contains seven lysine residues, each of
which can also serve as acceptor sites during ubiquitylation, leading
to the formation of polyubiquitin chains with different linkages
(Komander and Rape, 2012). Amongst these, K48- and K11-linked
chains typically serve to hallmark proteins for proteasomal
degradation (Komander and Rape, 2012). The 26S proteasome is
a multiprotein complex composed of a 20S catalytic core where
proteolysis occurs, and a 19S regulatory particle that controls
substrate entry (Bhattacharyya et al., 2014; Komander and Rape,
2012). Protein ubiquitylation can be reversed by the action of
proteases that are collectively known as deubiquitylating enzymes
(DUBs) (Komander and Rape, 2012; Komander et al., 2009), and
the removal of polyubiquitin by proteasomal DUBs precedes
substrate degradation at the catalytic core (Bhattacharyya et al.,
2014; Komander and Rape, 2012; Wauer and Komander, 2014).
Substrate delivery to the proteasome is facilitated by both
intrinsic (such as Rpn10 and Rpn13) (Husnjak et al., 2008; van
Nocker et al., 1996) and shuttle (such as Rad23 and ubiquilins)
ubiquitin receptors (Wang and Terpstra, 2013). Shuttle ubiquitin
receptors bind ubiquitylated proteins through ubiquitin-associated
domains (UBAs) and simultaneously interact with the proteasome
through their ubiquitin-like domains (UBLs) (Wang and Terpstra,
2013). Rpn10 and Rpn13 interact with the UBLs of such shuttle
factors, but can also bind directly to ubiquitylated substrates
(Bhattacharyya et al., 2014; Husnjak and Dikic, 2012; Husnjak
et al., 2008; van Nocker et al., 1996). It has been suggested that
effective proteasomal degradation requires simultaneous
recognition of the polyubiquitylated substrate by both the Rpn10
and Rpn13 subunits of the 19S regulatory particle (Bhattacharyya
et al., 2014; Kang et al., 2006; Komander and Rape, 2012; Sakata
et al., 2012). Substrates are subsequently deubiquitylated by Rpn11,
a 19S-localised DUB, helping to maintain the cellular pool of free
ubiquitin available for conjugation (Bhattacharyya et al., 2014;
Komander and Rape, 2012; Komander et al., 2009; Wauer and
Komander, 2014). Two additional DUBs, USP14 and UCHL5 (also
known as and hereafter referred to as UCH37), also associate with
the proteasome, although their precise roles are unclear (D’Arcy and
Linder, 2012; Komander and Rape, 2012; Lee et al., 2011). Hence,
whereas Rpn11 removes ubiquitin chains from proteasomal
substrates en bloc USP14 and UCH37 seem to preferentially
cleave off distal ubiquitin moieties, suggesting that they provide an
editing or quality control function that can rescue inefficiently or
prematurely ubiquitylated polypeptides (Bhattacharyya et al., 2014;
D’Arcy and Linder, 2012; Lee et al., 2011). The recruitment of
UCH37 to the proteasome is mediated by the C-terminal region of
Rpn13, indicating that substrate recognition and ubiquitin-chain
processing might be coupled (see D’Arcy and Linder, 2012;
Komander et al., 2009 and references therein).
The UPS plays a central role in protein quality control, providing
one of the primary routes by which the cell can remove potentially
deleterious, aberrant and misfolded proteins, and maintain cellular
protein homeostasis (Bhattacharyya et al., 2014; Buchberger et al.,
2010; Komander and Rape, 2012; Wang and Terpstra, 2013; WauerReceived 28 October 2014; Accepted 3 July 2015
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and Komander, 2014). Avariety of effectors operate upstream of the
UPS acting to recognise different classes of defective proteins and
regulate their selective removal (Buchberger et al., 2010; Wang and
Terpstra, 2013). Two such effectors are small glutamine-rich
tetratricopeptide repeat containing protein alpha (SGTA) and the
heterotrimeric BAG6 complex that, together, deal with polypeptide
substrates that inappropriately expose hydrophobicity to the cytosol
(Hessa et al., 2011; Leznicki and High, 2012; Minami et al., 2010;
Rodrigo-Brenni et al., 2014; Wunderley et al., 2014). Hence, SGTA
and the BAG6 complex are implicated in the quality control of
mislocalised and secretory proteins, collectively termed
mislocalised proteins (MLPs), which have failed to be correctly
delivered to the endoplasmic reticulum (ER) and, consequently,
become localised to the cytosol (Hessa et al., 2011; Leznicki and
High, 2012; Rodrigo-Brenni et al., 2014; Wunderley et al., 2014).
Current models suggest that BAG6 and SGTA can each recognise
a range of hydrophobic substrates located in the cytosol and direct
them to an appropriate biosynthetic or degradative route. Hence,
tail-anchored membrane proteins that follow a post-translational
pathway for membrane insertion encounter both SGTA and the
BAG6 complex prior to their TRC40-dependent integration at the
ER (Leznicki et al., 2010; Mariappan et al., 2010; Mock et al.,
2015). By contrast, the normal fate of hydrophobic substrates that
are unable to translocate into or across the ER membrane is rapid,
BAG6-facilitated, proteasomal degradation (Hessa et al., 2011;
Rodrigo-Brenni et al., 2014; Wunderley et al., 2014). Both
overexpression and knockdown studies indicate that SGTA
antagonises the actions of the BAG6 complex to delay the
proteasomal degradation of MLPs (Leznicki and High, 2012;
Wunderley et al., 2014). Furthermore, the N-terminal domain of an
SGTA homodimer can bind to the BAG6 complex through its two
ubiquitin-like domain (UBL)-containing subunits, providing a
physical link between these two quality control factors (Chartron
et al., 2012; Darby et al., 2014; Leznicki et al., 2013; Xu et al.,
2012). In the context of proteasomal degradation, BAG6 facilitates
the RNF126-dependent ubiquitylation and proteasomal degradation
of MLPs (Hessa et al., 2011; Rodrigo-Brenni et al., 2014), whereas
SGTA acts to inhibit MLP degradation, most probably by favouring
their deubiquitylation (Leznicki and High, 2012; Wunderley et al.,
2014). In a physiological context it has been suggested that the
SGTA-dependent antagonisation of BAG6 provides a rescue
pathway for potentially viable substrates – such as tail-anchored
proteins – that are prematurely ubiquitylated (Leznicki and High,
2012; Wunderley et al., 2014). Alternatively, cycles of substrate
ubiquitylation and deubiquitylation might normally help to facilitate
the selective degradation of MLPs (Brodsky, 2013; Zhang et al.,
2013).
In seeking so-far-unknown functions for the intrinsic
proteasomal ubiquitin receptor Rpn13, we identified a novel
interaction with SGTA. This interaction was initially suggested by
the results of a yeast two-hybrid screen and, subsequently, validated
using two different pull-down strategies, which showed that the
C-terminal region of Rpn13 binds to the central tetratricopeptide
repeat (TPR) domain of SGTA. Since Rpn13 acts as a proteasomal
ubiquitin receptor, we speculated that SGTA influences substrate
access to the proteasome. To test this hypothesis, we investigated the
potential role of the Rpn13–SGTA interaction in the proteasomal
degradation ofMLPs, a process previously shown to be regulated by
both SGTA (Leznicki and High, 2012; Wunderley et al., 2014) and
its interacting partner BAG6 (Hessa et al., 2011; Rodrigo-Brenni
et al., 2014). We show that the binding of exogenous SGTA to
Rpn13 results in a substantial increase in the steady-state level of
MLPs. Inhibiting this interaction by overexpression of the Rpn13
C-terminal region or mutation of the SGTATPR region negates the
effect of SGTA overexpression onMLP levels. These data support a
model whereby SGTA and its interacting partner the BAG6
complex can influence the fate of MLPs at the proteasome. We
speculate that these components modulate the access of such
substrates to the proteasome through their respective partners Rpn13
(this study) and Rpn10 (Kikukawa et al., 2005;Minami et al., 2010).
This model suggests that SGTA and BAG6 control the fate of MLPs
even after their arrival at the proteasome, and provides the basis for a
potential substrate rescue pathway and/or a mechanism to enhance
the selectivity of substrate degradation.
RESULTS
Rpn13 interacts with SGTA
To better understand the role of Rpn13 during proteasomal
degradation, we used full-length mouse Rpn13 (Rpn131-407), as well
as its N-terminal pleckstrin-like receptor for ubiquitin (Pru) domain
(amino acid residues 1–150; hereafter referred to as Rpn131-150) and
distinct C-terminal region (amino acid residues 150–407; hereafter
referred to as Rpn13150-407) (Fig. 1A), as baits in yeast two-hybrid
screens with a thymus cDNA library prey. This approach identified
SGTA as a potential interacting partner of Rpn13150-407 (data not
shown). To validate the yeast two-hybrid data, purified GST-tagged
Rpn13, Rpn131-150 and Rpn13150-407, were used as baits in pull-
down experiments primed with lysate from HeLa cells
overexpressing FLAG-tagged SGTA. This showed a specific
physical interaction of full-length Rpn131-407 and the Rpn13150-407
fragment with exogenous FLAG-SGTA (Fig. 2A, lanes 3–5). To
map the Rpn13-binding site on SGTA, a variety of SGTA deletion
mutants were purified as recombinant GST fusion proteins and their
interaction with exogenous FLAG-tagged Rpn13 present in HeLa
cell lysate was examined. This approach identified the central region
of SGTA, comprising residues 85-210, as necessary and sufficient
for Rpn13 binding (Fig. 2B, cf. lanes 3–7). This corresponds to the
Fig. 1. Domain organisation of Rpn13 and SGTA. (A,B) The discrete
domains present in Rpn13 (A) and SGTA (B) are indicated together with the
fragments of Rpn13 used for yeast two-hybrid analysis. For A: Pru, pleckstrin-
like receptor for ubiquitin, C, C-terminal region of Rpn13 that binds UCH37. For
B: N, N-terminal region responsible for both homo-oligomerisation and the
binding of ubiquitin-like domains (UBLs); TPR, tetratricopeptide-repeat-
containing domain; C, C-terminal glutamine-rich region implicated in binding to
hydrophobic substrates.
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central tetratricopeptide repeat (TPR) domain of SGTA (Fig. 1B), a
region previously implicated in binding both molecular chaperones
and viral proteins (Dutta and Tan, 2008; Fielding et al., 2006; Liou
and Wang, 2005; Walczak et al., 2014). In contrast to its interaction
with Rpn13, FLAG-SGTA did not bind to purified human Rpn10 or
its fragments (Fig. 2C, lanes 6–8), confirming the specificity of its
interaction with the Rpn13 ubiquitin receptor (Fig. 2C, cf. lanes
3–5). Since HeLa lysate is most likely to contain a number of
endogenous SGTA and/or Rpn13-binding partners, we further
tested the nature of the interaction by using recombinant Rpn13 and
SGTA. The SGTA–Rpn13 interaction could be recapitulated using
purified proteins (Fig. 2D and E), and we concluded that the two
components bind directly to each other.
Previous studies have shown that all cellular Rpn13 is
incorporated into the proteasome at steady state (Hamazaki et al.,
2006; Qiu et al., 2006), and we speculated that, in a cellular context,
the newly defined Rpn13–SGTA interaction mediates the
proteasomal recruitment of SGTA. To test this hypothesis, we
first purified proteasomes by using the HEK293Rpn11-HTBH cell line
that constitutively expresses a tagged form of the Rpn11 subunit in
addition to the endogenous protein (Wang et al., 2007). This cell
line provides a convenient approach to isolate native proteasomes
and has been used in several studies (Chen et al., 2010; Tsimokha
et al., 2014; Wang et al., 2010). We found that a small fraction of
endogenous SGTA was recovered with intact proteasomes
following their isolation by using a streptavidin pull down
(supplementary material Fig. S1, lanes 1–4). The association of
endogenous SGTA with the proteasome was most apparent when
cells had been pre-treated with the proteasome inhibitor MG132
prior to purification (supplementary material Fig. S1, cf. lanes 3 and
4). On the basis of these data, we concluded that Rpn13 provides a
binding site for SGTA at the proteasome, and we next explored the
functional consequences of this interaction. Whereas the increase in
proteasomal SGTA observed upon treatment with MG132 was
consistent with the stabilisation of a direct interaction with Rpn13
(cf. Fig. 2), we cannot rule out the alternative possibility that SGTA
also binds to Rpn13 through ubiquitylated substrates that
accumulate on the proteasome in the presence of the inhibitor
(Isakov and Stanhill, 2011).
SGTA promotes the proteasomal association of MLPs
The capacity of both SGTA and the Bag6 subunit of the
heterotrimeric BAG6 complex to bind hydrophobic polypeptides
(Hessa et al., 2011; Leznicki et al., 2013, 2011; Minami et al., 2010;
Fig. 2. SGTA interacts with Rpn13 in vivo and in vitro. (A–C) HeLa cells were transiently transfected with NpFLAG-CMV2-SGTA (A,C) or NpFLAG-CMV2-
mouse Rpn13 (B), lysed 24 h post-transfection and the soluble fraction incubated with GST-tagged proteins immobilised on Glutathione Sepharose beads as
indicated. Bound proteins were detected by western blotting with anti-FLAG antibody, whereas GST-tagged proteins were visualised by staining the membranes
with Ponceau S (see panel labelled Bait). GST-tagged tetraubiquitin (tetraUb) was used as a positive control for FLAG-Rpn13 binding. (D,E) Approximately
5 µg of purified recombinant SGTA (D) or Rpn13 (E) was incubatedwith equivalent amounts of indicated purified GST-tagged proteins immobilised onGlutathione
Sepharose beads and their binding followed by western blotting with anti-SGTA or anti-Rpn13 antibodies, respectively. Immobilised GST-tagged proteins
were visualised by Ponceau S staining of the membranes (Bait).
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Wunderley et al., 2014; Xu et al., 2012), and the proteasome (this
study; Kikukawa et al., 2005), raised the possibility that these
components modulate the fate of MLPs at the proteasome. To
address this question, SGTA and Bag6 were transiently
overexpressed in HEK293Rpn11-HTBH cells together with OP91, an
N-terminal fragment of the polytopic membrane protein opsin that
acts as anMLP (Wunderley et al., 2014). SGTA co-expression led to
a marked increase in steady-state OP91 in both HEK293Rpn11-HTBH
cells (Fig. 3A, OP91 panel, cf. lanes 4 and 6) and the parental line
(supplementary material Fig. S2A), consistent with previous studies
(Leznicki and High, 2012; Wunderley et al., 2014). Interestingly,
overexpression of the Bag6 protein had a similar effect on the level
of OP91 (Fig. 3A, OP91 panel, lanes 4 and 5), in agreement with the
previously reported dominant-negative effect exogenous Bag6
expression has on the degradation of aberrant membrane proteins
(Payapilly and High, 2014).
No proteasome-associated OP91 was apparent with the parental
cell line (supplementary material Fig. S2B, cf. OP91 panel).
Likewise, when intact proteasomes were isolated from
HEK293Rpn11-HTBH cells, OP91 was undetectable in the absence
of additional factors (Fig. 3B, OP91 panel, lane 4). By contrast,
OP91 was readily detectable when the proteasomal fraction was
isolated from cells that co-express exogenous SGTA (Fig. 3B, OP91
panel, cf. lanes 4 and 6). Notably, the proteasomal association of
this MLP substrate was mirrored by the recruitment of both
exogenous and endogenous SGTA to the proteasome [Fig. 3B,
SGTA-V5 (exogenous SGTA) and SGTApanels, cf. lanes 3, 4 and 6].
By contrast, although Bag6 co-expression led to a comparable
increase in steady-state levels of OP91 (Fig. 3A, OP91 panel, cf.
lanes 4–6), the amount of proteasome-associated OP91 was much
lower (Fig. 3B, OP91 panel, cf. lanes 4–6). Likewise, the recovery
of exogenous Bag6 with the proteasome appeared unaffected by
OP91 co-expression (Fig. 3B, Bag6-V5 panel, cf. lanes 2 and 5,
red circles). Interestingly, Bag6 co-expression with OP91 did appear
to enhance the proteasomal recruitment of endogenous SGTA
(Fig. 3B, SGTA panel, cf. lanes 2, 4 and 5, see component labelled
‘end.’). In short, the enhanced steady-state MLP levels observed
upon SGTA overexpression correlate with a specific increase in the
binding of both OP91 and SGTA to the proteasome. Given that
SGTA is known to bind a variety of hydrophobic substrates,
including MLPs and tail-anchored membrane proteins (Leznicki
et al., 2010, 2011; Liou and Wang, 2005; Wunderley et al., 2014),
we conclude that proteasome-associated SGTA might influence
MLP stability by regulating the access of such substrates to the
catalytic core. To test this hypothesis, we explored the outcome of
perturbing the Rpn13-dependent binding of exogenous SGTA to the
proteasome.
SGTA binding to Rpn13 regulates MLP stability
Our data show that SGTA binds to a C-terminal region of Rpn13,
Rpn13150-407, that is distinct from the N-terminal Pru domain, which
interacts with the proteasome and ubiquitin (Chen et al., 2010;
Husnjak et al., 2008; Schreiner et al., 2008). On this basis, we
speculated that overexpression of SGTA increases its occupancy of
Rpn13, thereby antagonising the proteasomal degradation of MLPs
and resulting in an increase of their steady-state expression level
(Fig. 3A; see also Wunderley et al., 2014). To test this hypothesis,
we investigated the effect of Rpn13 overexpression on the
association of exogenous SGTA with proteasomes (cf. Fig. 3;
supplementary material Figs S1 and S2). Although exogenous V5-
tagged SGTA was expressed under all conditions tested (Fig. 4Ai
and Bi, see SGTA panel), it was only detected in the proteasome-
associated fraction recovered from cells expressing HTBH-tagged
Rpn11 after treatment with MG132 [Fig. 4Aii and Bii, SGTA panel,
product labelled ex(V5).]. Notably, the amounts of exogenous
SGTA and its endogenous counterpart that were recovered with the
proteasome are both reduced upon Rpn13150-407 co-expression
(Fig. 4Bii, SGTA panel, lanes 2 and 8). By contrast, although
present at higher levels (Fig. 4Ai and Bi, FLAG-Rpn13 panel; see
also Fig. 5), overexpression of full-length Rpn13, or of its N-
terminal fragment, have far less of an effect on the proteasomal
association of SGTA (Fig. 4Bii, SGTA panel, lanes 2, 4, 6 and 8).
On this basis, we conclude that – when overexpressed – the C-
terminal Rpn13150-407 fragment can compete for binding to
available SGTA, thereby reducing its association with the
proteasome.
We next asked whether a reduction of the proteasome-associated
fraction of exogenous SGTA by overexpressing Rpn13150-407 has
Fig. 3. OP91 and SGTA co-purify with the proteasome
when co-expressed. (A,B) HEK293Rpn11-HTBH cells were
transiently transfected with plasmids encoding the
indicated proteins (lanes 2–6) or an empty vector control
(lanes 1). Total cell lysates (A) and proteasomal fractions
isolated by using streptavidin beads (B), and were
analysed by western blotting with appropriate antibodies
for the presence of the MLP substrate, OP91, exogenous
Bag6-V5, exogenous SGTA-V5, endogenous Bag6 and
endogenous SGTA. Proteasomal recovery was confirmed
by using antibodies against subunits of the 20S (20S), and
19S (PSMD1) proteasome as indicated (see also
supplementary material Fig. S1). Endogenous (end.) and
exogenous [ex(V5).] SGTA are identified, as is
overexpressed Bag6-V5 recovered with the proteasome
(red circles). *, Non-specific, crossreacting species (see
also supplementary material Fig. S2).
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any impact on the fate of OP91 (see Fig. 3) and an alternative MLP
OPG-TASK85 that is derived from the K
+-channel TASK-1
(Wunderley et al., 2014). Co-expression of Rpn13150-407 and the
MLPs alone led to a reduction in detectable amounts of OP91and
OPG-TASK85 (Fig. 5A and B, lanes 1 and 4, see also accompanying
graphs); suggesting that the Rpn13150-407-mediated displacement of
endogenous SGTA (Fig. 4Bii) reduces steady-state levels of MLP.
The effect of Rpn13150-407 co-expression is much more striking
when exogenous SGTA is present, with steady-state levels of MLP
approaching those seen without exogenous SGTA (Fig. 5A and B,
cf. lanes 1, 5 and 8; see also accompanying graphs). Co-expressing
full-length Rpn13 with exogenous SGTA had an effect that is
comparable with that of Rpn13150-407 for the MLP substrate OPG-
TASK85, but is more-modest in the case of OP91 (Fig. 5A and B,
lanes 5–8). By contrast, co-expression of the N-terminal Rpn131-150
domain in combination with SGTA has relatively little effect
(Fig. 5A and B, cf. lanes 5, 7 and 8). The substrate specificity of
these effects was explored by using ubiquitin–arginine–GFP (Ub-
R-GFP) (Dantuma et al., 2000), a proteasomal N-end rule substrate
that appears to be insensitive to changes in SGTA levels (Leznicki
and High, 2012; Wunderley et al., 2014). Despite comparable levels
of expression of SGTA and all three Rpn13 variants (Fig. 5A–C),
steady-state levels of Ub-R-GFP were essentially unaltered by any
of the combinations tested (Fig. 5C, lanes 1–8; and accompanying
graph). On the basis of these results, we conclude that the ability of
exogenous SGTA to enhance steady-state MLP levels is strongly
dependent upon its binding to the C-terminal region of Rpn13.
Given that the central TPR domain of SGTA (Fig. 1B) is
responsible for binding Rpn13 (see Fig. 2B), we speculated that this
interaction is sensitive to point mutations that perturb the binding of
other components to this region (Walczak et al., 2014). Hence, a
previously defined K160E/R164E mutant version of SGTA that is
defective in binding to Hsc70 was created (Walczak et al., 2014; Xu
et al., 2012) and its ability to bind Rpn13 tested. Whereas a
recombinant fusion protein containing wild-type SGTA (Leznicki
and High, 2012) bound to both full-length Rpn13 and its C-terminal
domain (Fig. 6A, His Trx-SGTA panel), no interaction with the
K160E/R164E variant was detected (Fig. 6B, His Trx-SGTA
panel). Likewise, when equivalent versions of these SGTAvariants
were expressed in parental HEK293T or HEK293Rpn11-HTBH cells
(Fig. 6Ci and Di), the amount of the SGTA K160E/R164E-V5
mutant recovered with the proteasome was substantially reduced
[Fig. 6Dii, SGTA panels, lanes 3–6, see product labelled ex(V5).].
On this basis, we conclude that the SGTA K160E/R164E mutant is
defective in its Rpn13-mediated association with the proteasome.
Finally, we used the SGTA K160E/R164E mutant as an alternative
tool to test the contribution of the proteasomal binding of SGTA to
its role in MLP quality control. Once again (Figs 3 and 5; see also
Wunderley et al., 2014), overexpression of SGTA-V5 led to a
substantial increase in OP91 (Fig. 6E, OP91 panel, cf. lanes 1 and 2),
with a four-fold increase in its steady-state level (Fig. 6F).
Strikingly, although both versions of SGTA-V5 were expressed at
the same level (Fig. 6E, V5 panel, lanes 2 and 3), the K160E/R164E
mutant was far less effective at enhancing the steady-state level of
Fig. 4. The Rpn13 C-terminal region
inhibits binding of SGTA to the
proteasome. (Ai–Bii) Parental
HEK293T cells (Ai and Aii) or
HEK293Rpn11-HTBH cells that express
an exogenous tagged form of Rpn11
(Bi and Bii) were transiently co-
transfected with pcDNA5-SGTA-V5
and empty NpFLAG-CMV2 plasmid
(lanes 1 and 2) or NpFLAG-CMV2
encoding the indicated variants of
Rpn13 (lanes 3–8). Cells were treated
as indicated with 10 µM MG132 or
DMSO (solvent control) for 16 h, and
then total cell lysates (Ai,Bi), or
proteasomal fractions isolated under
native conditions using streptavidin
beads (Aii,Bii) were prepared. The
samples were analysed for
endogenous (end.) and exogenous
[ex(V5).] SGTA and FLAG-Rpn13
variants (FLAG-Rpn13) by western
blotting. Proteasomal recovery was
confirmed by western blotting for 20S
components and PMSD1 (cf. Fig. 3).
*, Non-specific, crossreacting, species
detected by certain antibodies.
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OP91 (Fig. 6E, OP91 panel, lanes 2 and 3; Fig. 6F). We, therefore,
conclude that the binding of SGTA to the Rpn13 subunit of the
proteasome makes an important contribution to the role of SGTA
during the quality control of MLPs.
DISCUSSION
Hydrophobic MLPs enter a cytosolic quality control pathway that
appears to be mediated by the coordinated activity of the BAG6
complex and SGTA (Hessa et al., 2011; Leznicki and High, 2012).
Hence, BAG6 promotes the RNF126-dependent ubiquitylation and
proteasomal degradation of MLPs (Hessa et al., 2011; Rodrigo-
Brenni et al., 2014), whereas SGTA acts to delay their degradation
and promotes the accumulation of deubiquitylated MLPs (Leznicki
and High, 2012; Wunderley et al., 2014). We now show that SGTA
is selectively recruited to the proteasome through Rpn13, and
provide evidence that this interaction may regulate MLP stability.
Using yeast two-hybrid and biochemical approaches, we identify a
direct physical interaction between the TPR region of SGTA and the
C-terminal region of Rpn13. Treatment with MG132 results in a
fraction of endogenous SGTA becoming stably associated with the
proteasome, consistent with our proposal that these components
interact in a cellular context.
Our previous studies indicated that SGTA antagonises the BAG6-
dependent ubiquitylation and proteasomal degradation of MLPs, a
role that is particularly apparent when cellular SGTA levels are
increased following its overexpression (Leznicki and High, 2012;
Wunderley et al., 2014).We now offer amolecular basis for this effect
by providing evidence that SGTA can regulate the access of MLPs to
the proteasomal core in a manner that leaves other substrates, as
exemplified by Ub-R-GFP, unaffected. Thus, the increased MLP
levels observed upon SGTA overexpression correlatewith an increase
in the association of the MLP, and both exogenous and endogenous
SGTA, with the proteasome. Similar to the effect of an SGTA
knockdown (Wunderley et al., 2014), co-expression of an Rpn13 C-
terminal region reduces steady-state MLP levels, and our data are
consistent with a partial displacement of endogenous SGTA from the
proteasome. This effect of Rpn13 is even more striking in the context
of SGTA overexpression, which normally stabilises MLPs leading to
their non-physiological accumulation (Wunderley et al., 2014). Under
these circumstances, Rpn13150-407 co-expression substantially
reduces the binding of exogenous SGTA to the proteasome and
reverses the SGTA mediated increase in steady-state MLP levels.
These findings are consistent with a model in which Rpn13-bound
SGTA binds to MLPs and delays their proteasomal degradation (see
Fig. 7; cf. Wunderley et al., 2014).
The significance of the interaction between SGTA and the
proteasome during the quality control of MLPs is further supported
by an SGTA variant with an altered TPR region (cf. Walczak et al.,
2014). Hence, the loss of proteasome binding observed with the
SGTA K160E/R164E mutant is accompanied by a substantial
reduction in its effectiveness at enhancing steady-state MLP levels.
Like Rpn13, Rpn10 is also an intrinsic ubiquitin receptor of the
Fig. 5. Exogenous Rpn13 reverses SGTA-mediated increase in MLP levels. (A–C) HeLa cells were co-transfected with plasmids encoding OP91 (A),
OPG-TASK85 (B) or Ub-R-GFP (C), together with pcDNA5-SGTA-V5, or a control vector, and NpFLAG-CMV2 encoding the indicated variants of Rpn13 or empty
NpFLAG-CMV2 plasmid as indicated. Substrate levels were examined 22 h post-transfection by quantitative western blotting of total cell lysate, the resulting
signals normalised to tubulin and plotted relative to the amount of substrate in control cells (lane 1 in each panel). The values show standard errors; n≥3.
Overexpressed exogenous SGTA and Rpn13 were visualised by western blotting with antibodies recognising the V5 or FLAG tags.
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Fig. 6. An SGTAmutant that is impaired in proteasome binding is also defective in enhancingMLP levels. (A,B) Approximately 5 µg of purified recombinant
His Trx-SGTA (A) or His Trx-SGTA K160E/R164E (B) was incubated with equivalent amounts of immobilised GST (lane 1) or immobilised GST-tagged Rpn13
derivatives (lanes 2–5), and bound recombinant SGTAwas visualised by western blotting with an anti-His tag antibody. Immobilised GST-tagged proteins were
visualised by Ponceau S staining of the membranes (Bait). (Ci–Dii) Parental HEK293T cells (Ci, Cii), or HEK293Rpn11-HTBH cells (Di, Dii), were transiently
transfected with a control vector (lanes 1 and 2), or plasmids encoding V5 tagged SGTA variants (lanes 3–6), as indicated. Treatment with MG132, and sample
processing and analysis were as described for Fig. 4. Endogenous (end.) and exogenous [ex(V5).] SGTAwere detected by western blotting, and both short and
long exposures of the resulting enhanced chemiluminescence signals are shown. (E) HeLa Flp-In T-REx cells overexpressing OP91 under an inducible promoter
were transiently transfected with either a control plasmid (Pex19-V5, lane 1) or plasmids encoding V5-tagged SGTA variants as indicated (lanes 2 and 3),
grown overnight, and then induced to express OP91. Cells were harvested the following day and OP91 levels were determined by quantitative western blotting of
total cell lysate. (F) The resulting OP91 signals were normalised to tubulin and expressed relative to the amount of substrate in control cells (lane 1) with standard
errors for n=3. Overexpressed exogenous Pex19 and SGTA variants were also visualised by western blotting for their V5-tag.
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proteasome (Bhattacharyya et al., 2014; van Nocker et al., 1996),
and it has previously been reported to bind to Bag6 (Kikukawa et al.,
2005; Minami et al., 2010). Interestingly, the overexpression of
Rpn10 leads to amodest increase in steady-stateMLP levels, and this
effect appears to be cumulative with the more pronounced effect of
SGTA overexpression (supplementary material Fig. S3). It has been
suggested that a single polyubiquitin chain can be captured by both
the Rpn10 and Rpn13 ubiquitin receptors (Bhattacharyya et al.,
2014; Sakata et al., 2012) and, given their proximity, we propose that
Rpn13-bound SGTA and Rpn10-bound BAG6 can modulate the
access of MLPs to the proteasome (cf. Fig. 7). This model is also
supported by the finding that disrupting the interaction of SGTAwith
the N-terminal UBL of Bag6 reverses the ability of the exogenous
protein to stabilise MLPs (Wunderley et al., 2014). Hence, the
interaction of SGTA with both Rpn13 and the BAG6 complex
appear to be important for its role in protein quality control (Fig. 7).
In addition to binding SGTA (this study), the C-terminal region
of Rpn13 has also been shown to bind and activate UCH37 at the
19S proteasome (Bhattacharyya et al., 2014; Hamazaki et al., 2006;
Yao et al., 2006). On this basis, we speculate that – following the
arrival of MLPs at the proteasome – SGTA controls the access of
these substrates to proteasome-associated DUBs (Fig. 7) and, thereby,
influencesMLP degradation (Wunderley et al., 2014), consistent with
the effects on steady-state MLP levels that we observed in this study.
Although we had previously suggested that proteasomal components
are dispensable for the SGTA-mediated stabilisation of MLPs
(Leznicki and High, 2012), it is now apparent that MLPs can be
dealt with by alternate cellular quality control pathways that are – at
least partially – redundant in nature (Rodrigo-Brenni et al., 2014).
Interestingly, UCH37-mediated deubiquitylation can either suppress
or promote polypeptide degradation in a substrate-specific manner
(D’Arcy and Linder, 2012; Lee et al., 2011) and, hence, SGTAmight
impact on either of these potential fates for MLPs. We speculate that,
in a physiological context, BAG6/SGTA-dependent cycles of
substrate ubiquitylation and deubiquitylation are able to distinguish
between aberrantly and correctly folded precursor proteins, thereby
enhancing the fidelity of quality control (Brodsky, 2013; Wunderley
et al., 2014; Zhang et al., 2013). Alternatively, SGTA binding and/or
SGTA-facilitated deubiquitylation might provide a ‘rescue pathway’
for endogenous hydrophobic substrates, such as tail-anchored
proteins, that might be prone to premature ubiquitylation (Ast et al.,
2014; Leznicki and High, 2012; Wunderley et al., 2014). In the latter
case it is noteworthy that, in addition to providing the binding site for
Rpn13 (this study), the TPR domain of SGTA can also interact with
Hsp70 and Hsp90 chaperones (Liou andWang, 2005; Walczak et al.,
2014), thereby providing substrates with potential access to additional
quality control factors (cf. Fig. 7). Such a system would allow a
putative BAG6/SGTA cycle to provide a proteasomal triage pathway,
enabling aberrant precursors several attempts at productive folding/
ER delivery before they are committed to degradation, and ensuring
that the delivery of precursor proteins into competing pathways for
maturation and degradation is carefully controlled (Fig. 7) (Leznicki
and High, 2012; Wunderley et al., 2014).
MATERIALS AND METHODS
Materials
Standard molecular biology techniques were used to clone the variants of
mouse Rpn13, human Rpn10 and human SGTA into pGEX-4T1 vector for
bacterial production of GST-tagged recombinant proteins. The His Trx-
SGTA fusion protein is as previously described (Leznicki et al., 2011).
Plasmid pGEX-4T2- TetraUb was a kind gift of Caixia Guo and Errol
Friedberg (University of Texas, Dallas, TX). For expression in mammalian
cells, full-length Rpn13 and SGTA were cloned into NpFLAG-CMV2
plasmid, whereas full-length Rpn10 was in pcDNA3.1-myc. Where used,
SGTA-V5, Bag6-V5 and OP91 were in pcDNA5 and OPG-TASK85 in
pcDNA3.1 are as previously described (Leznicki and High, 2012;
Wunderley et al., 2014). The K160E/R164E mutant of SGTA is defective
for Hsp70 binding (Walczak et al., 2014; Xu et al., 2012), and was generated
by site-directed mutagenesis and validated by DNA sequencing prior to use.
The Ub-R-GFP cDNA was obtained from Addgene (plasmid number
11939) deposited by Nico Dantuma (Karolinska Institute, Sweden)
(Dantuma et al., 2000), and re-cloned into pcDNA5 vector using a TOPO
cloning kit (Invitrogen).
Anti-Rpn13 and anti-20S proteasome antibodies were obtained from
Enzo Life Sciences, anti-FLAG M2 antibody from Sigma, anti-Myc
antibody (clone 4A6) from Upstate and anti-His tag antibody from
Novagen. Mouse anti-SGTA antibody (clone 47-B) was purchased from
Santa Cruz Biotechnology, whereas a chicken anti-SGTA antibody was
made to order. Mouse anti-tubulin antibody was a gift from Keith Gull
(University of Oxford, UK). Rabbit anti-tubulin, rabbit anti-GFP, rabbit
anti-PSMD1 and chicken anti-Bag6 antibodies were from Abcam, whereas
mouse anti-V5 antibody was purchased from Abcam and Serotec. The
monoclonal anti-opsin tag antibody has been previously described
(Leznicki et al., 2010). The HEK293 cell line stably expressing the
hRpn11-HTBH plasmid (HEK293Rpn11-HTBH) was a kind gift of Lan Huang
(University of California, Irvine, CA) (Wang et al., 2007). Stable,
tetracycline-inducible HeLa Flp-In T-REx cells used to generate a stable
line expressing OP91 were from Stephen Taylor (University of Manchester,
UK) (Tighe et al., 2008; Wunderley et al., 2014).
Recombinant protein production and GST pull-down assay
Escherichia coli strain BL21 transformed with the pGEX-4T1 plasmid
encoding a GST-tagged protein of interest was grown to OD600=0.5;
expression was induced with 0.5 mM IPTG followed by overnight
incubation at 16°C. Cells were harvested, lysed by sonication in lysis
Fig. 7. Model describing the modulation of MLP quality control at the
proteasome by BAG6 and SGTA. The heterotrimeric BAG6 complex,
composed of Bag6, TRC35 and UBL4A, recognises cytosolic MLPs and
stimulates their ubiquitylation. It might also contribute to substrate delivery to
the proteasome following the interaction of the Bag6 subunit with Rpn10
(Kikukawa et al., 2005;Minami et al., 2010). SGTA is recruited to theC-terminal
region of Rpn13 through its central TPR domain (this study), in concert with
MLPs that might bind to SGTA and/or the Pru domain of Rpn13, depending on
their ubiquitylation status. The proteasome-associated deubiquitylase UCH37
also binds Rpn13 (Bhattacharyya et al., 2014; Hamazaki et al., 2006;
Yao et al., 2006), providing a potential molecular basis for a putative ‘rescue
pathway’ that facilitates the deubiquitylation of previously modified MLPs
(Leznicki and High, 2012; Wunderley et al., 2014). The proximity of the Rpn10
and Rpn13 subunits (Bhattacharyya et al., 2014) is consistent with the
suggestion that, following delivery to the proteasome, substrates undergo
cycles of ubiquitylation and deubiquitylation in response to the respective
actions of the BAG6 complex and SGTA (Hessa et al., 2011; Leznicki and
High, 2012; Rodrigo-Brenni et al., 2014; Wunderley et al., 2014). The Hsp70
and Hsp90 molecular chaperones could also contribute to this hypothetical
quality-control process (Liou and Wang, 2005; Walczak et al., 2014).
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buffer [20 mM Tris-HCl pH 7.5, 10 mM EDTA, 5 mM EGTA, 150 mM
NaCl, 0.5% (v/v) Triton X-100] and insoluble material pelleted by
centrifugation (20 min, 4°C, 10,000×g). Pre-equilibrated Glutathione
Sepharose 4B beads (GE Healthcare) were added to the supernatant,
incubated for 1 h at 4°C and extensively washed with the lysis buffer. Bound
GST fusion proteins were either stored on the resin at 4°C or released by
using thrombin (GEHealthcare) at 24°C in 1× cleavage buffer (20 mMTris-
HCl, pH 8.4, 150 mM NaCl, 2.5 mM CaCl2, 1 mM DTT) overnight. Beads
were then pelleted by centrifugation and thrombin was inactivated with
PMSF. The interaction between purified components was followed by
incubating one Glutathione-Sepharose-bound protein with a potential
binding partner that had been released from its GST tag through thrombin
cleavage. The His-tagged Trx-SGTA fusion protein and a K160E/R164E
mutant version were expressed and purified as previously described
(Leznicki et al., 2011). Binding reactions were performed in 1×
incubation buffer [20 mM Tris-HCl pH 8.4, 150 mM NaCl, 2.5 mM
CaCl2, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1 mM DTT] for 4 h at
4°C, beads washed extensively with incubation buffer, SDS sample buffer
added and samples resolved by SDS-PAGE followed by western blotting.
For pull-down experiments from mammalian cell lysate, HeLa cells were
transiently transfected with the indicated plasmids using GeneJuice (Merck)
according to manufacturer’s instruction. After 24 h cells were lysed in ice-
cold lysis buffer [50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 25 mM NaF,
10 mM ZnCl2] freshly supplemented with complete protease inhibitor
cocktail (Roche) and, after a pre-clearing centrifugation step (20 min,
13,000×g, 4°C), the soluble fraction was incubated for 4 h at 4°C with
recombinant proteins immobilised on Glutathione Sepharose resin. Beads
were washed with lysis buffer, bound proteins eluted with SDS sample
buffer and subjected to SDS-PAGE and western blotting.
Additional cell culture techniques
To purify the proteasomal fraction, parental HEK293T or HEK293Rpn11-HTBH
cells were transfected with the indicated plasmids using GeneJuice (Merck)
and then lysed 24 h post-transfection in ice-cold buffer (50 mM sodium
phosphate, pH 7.5, 100 mM NaCl, 5 mMMgCl2, 10% (v/v) glycerol, 0.5%
(v/v) NP-40) freshly supplemented with complete protease inhibitor cocktail
(Roche), 5 mM ATP and 1 mM DTT. The resulting lysate was pre-cleared
by centrifugation (20 min, 13,000×g, 4°C), and supernatants were incubated
with streptavidin beads (Thermo Scientific) at 4°C overnight. The resin was
washed with lysis buffer and bound proteins were eluted with SDS sample
buffer and resolved by SDS-PAGE followed by western blotting. For
comparison, a fraction of the total lysates, equivalent to 1% of the input used
for the pull-down experiment, was analysed in parallel.
The effect of expression of isolated proteasomal ubiquitin receptors was
addressed by co-transfecting HeLa cells grown in 12-well cell culture dishes
with a combination of 0.5 µg substrate DNA, 0.2 µg pcDNA5-SGTA-V5 or
control vector and 0.3 µg plasmid encoding the Rpn13 variant, Rpn10 or
appropriate empty vector controls using Lipofectamine 2000 (Invitrogen)
according to manufacturer’s instruction. Cells were processed 22 h post-
transfection as previously described (Leznicki and High, 2012) and results
visualised by quantitative western blotting (LiCor Biosciences). The effects
of overexpressing SGTA-V5 and the K160E/R164E mutant version were
monitored by using a TRex Flp-In HeLa cell line stably expressing OP91
under the control of a tetracycline-inducible promoter. After transfection
with plasmids expressing V5-tagged SGTA variants, or a Pex19 control,
samples were grown for 24 h. Cells were then induced by treatment with
1 µg/ml tetracycline, grown for further 24 h, harvested directly into sample
buffer and analysed by quantitative western blotting (cf. Wunderley et al.,
2014). For the quantification of substrate levels, the relevant experiments
were independently repeated at least three times, the amount of substrate
quantified with Odyssey 2.1 software and plotted relative to the matched
control using GraphPad Prism 4.0 software.
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